Fortrea Holdings (FTRE) EPS (Basic) (2022 - 2026)

Fortrea Holdings (FTRE) posted EPS (Basic) of -$0.25 for Q1 2026, down 277.69% on a QoQ basis from $0.14 in Q4 2024.

Fortrea Holdings (FTRE) EPS (Basic) (2022 - 2026) Analysis & Trends

Fortrea Holdings' EPS (Basic) history runs 4 years deep, the most recent figure standing at -$0.25 for Q1 2026.

Quarterly EPS (Basic) changed N/A year-over-year to -$0.25 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.25 (up 36.54% YoY) and the FY2024 annual result came in at -$0.64, down 970.06% from the prior year.
EPS (Basic) was -$0.25 for Q1 2026 at Fortrea Holdings, down from $0.14 in the prior quarter.
Across five years, EPS (Basic) topped out at $0.75 in Q2 2022 and bottomed at -$0.44 in Q2 2024.
A 4-year average of $0.04 and a median of -$0.02 in 2023 frame the typical range for EPS (Basic).
Peak annual rise in EPS (Basic) reached 313.57% in 2024, while the deepest fall reached 769.61% in 2024.
Fortrea Holdings' EPS (Basic) stood at -$0.15 in 2022, then surged by 56.62% to -$0.07 in 2023, then jumped by 313.57% to $0.14 in 2024, then plunged by 277.69% to -$0.25 in 2026.
Business Quant data shows FTRE's EPS (Basic) at -$0.25 in Q1 2026, $0.14 in Q4 2024, and -$0.1 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	0.00
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.16
4	NuCana	279.75 Bn	279.75 Bn	-	0.00
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	4.06
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	6.99
7	Belite Bio	62.51 Bn	62.51 Bn	-	0.00
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	7.59
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-2.29
10	Fortrea Holdings	1.83 Bn	1.68 Bn	123.60 Mn	-0.25

Download Data